共 50 条
Effect of a monoclonal antibody against human relaxin-2 on cancer cell growth inhibition
被引:3
|作者:
Park, Byoung Kwon
[1
,2
]
Lee, Su In
[2
]
Lee, Younghee
[3
]
Cho, Sooyoung
[4
]
Lee, Young Seek
[5
]
Kwon, Hyung-Joo
[1
,2
]
机构:
[1] Hallym Univ, Coll Med, Ctr Med Sci Res, Chunchon 24252, South Korea
[2] Hallym Univ, Coll Med, Dept Microbiol, Chunchon 24252, South Korea
[3] Chungbuk Natl Univ, Dept Biochem, Coll Nat Sci, Cheongju 28644, South Korea
[4] Seoul Natl Univ, Res Inst Vet Sci BK21, Lab Dev Biol & Genom, Coll Vet Med,Program Vet Sci, Seoul 08826, South Korea
[5] Hanyang Univ, Div Mol & Life Sci, Coll Sci & Technol, Ansan 15588, South Korea
基金:
新加坡国家研究基金会;
关键词:
Cancer;
Monoclonal antibody;
Relaxin-2;
DNA-LIPOSOME COMPLEX;
XENOGRAFT TUMOR-GROWTH;
CPG-DNA;
INCREASES SECRETION;
CERVICAL GROWTH;
IN-VIVO;
PROGRESSION;
EXPRESSION;
PIG;
OSTEOSARCOMA;
D O I:
10.1007/s13765-016-0221-4
中图分类号:
TS2 [食品工业];
学科分类号:
0832 ;
摘要:
Relaxin-2 has gained much attention because of its importance in cancer cell proliferation, invasion, and angiogenesis. However, the potential of relaxin-2 as a target for immunotherapy has never been directly validated before. In the present study, we produced a human relaxin-2-specific antibody by immunizing mice using a specific liposome complex containing relaxin-2 epitope peptide and CpG-DNA. We isolated a hybridoma clone, 1B11F12, producing the anti-relaxin-2 monoclonal antibody. We confirmed with immunoprecipitation analysis that the antibody specifically recognizes native human relaxin-2. Treatment with the antibody suppressed the growth of some cancer cell lines. Therefore, we suggest that relaxin-2 could be a reasonable target of cancer therapeutics, and the monoclonal antibody could be used to treat cancer in humans.
引用
收藏
页码:739 / 746
页数:8
相关论文